Search results for "Lymphoblastic Leukemia"

showing 10 items of 85 documents

Verrucous Plaque With Unusually Large Candida Blastoconidia: A Unique Clinicopathological Presentation of Systemic Mucocutaneous Candidiasis.

2018

Mucocutaneous candidiasis is a common infection affecting both immunocompetent and immunosuppressed individuals. Diversity in the clinical and histopathological presentation of mucocutaneous candidiasis is well known. However, the occurrence of cutaneous verrucous lesions and giant yeast-like structures has been rarely reported. In this article, we describe a case of disseminated mucocutaneous candidiasis in an immunosuppressed patient who presented as a verrucous plaque on the scrotum with giant Candida blastoconidia. This peculiar presentation expands the clinicopathological spectrum of mucocutaneous candidiasis and highlights the wide range of clinical manifestations and great morphologi…

0301 basic medicineMalemedicine.medical_specialtyAdolescent030106 microbiologychronic mucocutaneous candidiasisDermatologyMucocutaneous CandidiasisBlastoconidiumPathology and Forensic MedicinePrecursor Cell Lymphoblastic Leukemia Lymphoma030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicinegiant blastoconidiaScrotummedicineHumansCandidiasis chronic mucocutaneousCandidabusiness.industryCandidiasis Chronic MucocutaneousHematopoietic Stem Cell TransplantationVerrucous LesionGeneral Medicineatypical candidiasisPrecursor Cell Lymphoblastic Leukemia-LymphomaSpores FungalDermatologymedicine.anatomical_structurecandidaScrotumPresentation (obstetrics)businessThe American Journal of dermatopathology
researchProduct

Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors

2018

Vitamin D (25-OHD) has a role in bone health after treatment for cancer. 25-OHD deficiency has been associated with risk factors for cardiovascular disease, but no data focusing on this topic in childhood cancer survivors have been published. We investigated the 25-OHD status in children treated for acute lymphoblastic leukemia (ALL), and evaluated its influence on vascular function. 25-OHD levels were evaluated in 52 ALL survivors and 40 matched healthy controls. Patients were grouped according to 25-OHD level (< 20 ng/m or ≥ 20 ng/ml). Auxological parameters, biochemical and hemostatic markers of endothelial function (AD, HMW-AD, ET-1, vWFAg, TAT, D-dimers, Fbg, and hs-CRP), ultrasound ma…

Malemedicine.medical_specialtyendocrine system diseasesAdolescentDiseaseAcute lymphoblastic leukemiaurologic and male genital diseasesGastroenterologyC-IMT03 medical and health sciencesYoung Adult0302 clinical medicineRisk Factors030225 pediatricsmedicine.arteryInternal medicinePediatric surgerymedicineVitamin D and neurologyHumans030212 general & internal medicineSurvivorsVitamin DChildChildhood Acute Lymphoblastic LeukemiaUnivariate analysisbusiness.industryAbdominal aortaConfoundingnutritional and metabolic diseasesCancerPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVitamin D DeficiencyCardiovascular diseaseChild PreschoolPediatrics Perinatology and Child HealthFemaleEndothelium VascularbusinessBiomarkersVascular ultrasound studie
researchProduct

Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice.

2014

Therapeutic natural killer (NK)-cell-mediated alloreactivity toward acute myeloid leukemia has largely been attributed to mismatches between killer immunoglobulin-like receptors (KIRs) on NK cells and their ligands, HLA class I molecules, on target cells. While adult acute B-cell precursor leukemia (BCP-ALL) appears to be resistant to NK-cell-mediated lysis, recent data indicate that pediatric BCP-ALL might yet be a target of NK cells. In this study, we demonstrate in a donor-patient-specific NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate considerable alloreactivity toward pediatric BCP-ALL in vivo. Notably, both adoptively transferred mature KIR(+)…

Cytotoxicity ImmunologicGenotypeXenotransplantationmedicine.medical_treatmentImmunologyTransplantation HeterologousAntineoplastic AgentsGraft vs Leukemia EffectHuman leukocyte antigenBiochemistryMiceImmune systemReceptors KIRMice Inbred NODPrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAnimalsHumansChildB cellSevere combined immunodeficiencybusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaCell BiologyHematologyDNA Methylationmedicine.diseasePrognosisTransplantationKiller Cells NaturalLeukemiaDisease Models Animalmedicine.anatomical_structureImmunologyAzacitidineCytokinesInterleukin-2businessBlood
researchProduct

Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia

2002

Background Antimetabolite-based continuation therapy is commonly used for childhood acute lymphoblastic leukemia (ALL) and hypoglycemia after prolonged fasting has been recently reported. We have found that spontaneous, symptomatic hypoglycemia (SH) may also occur in such patients. Procedure Between 1995 and 1999, patients treated according to the AIEOP-ALL-95 study received BFM-type intensive chemotherapy; mercaptopurine (6-MP) was given (60 mg/m2/days, orally for 14 days) during the second part of induction and during consolidation therapy (25 mg/m2/day, orally for 8 weeks); thioguanine (6-TG) was given during reinduction therapy with protocol II (60 mg/m2/day, orally for 14 days); contin…

Cancer ResearchChemotherapyVincristinemedicine.medical_specialtymedicine.drug_classbusiness.industrymedicine.medical_treatmentHypoglycemiamedicine.diseaseGastroenterologyMercaptopurineAntimetaboliteSurgeryTioguanineOncologyAcute lymphocytic leukemiaInternal medicinePediatrics Perinatology and Child HealthmedicinebusinessChildhood Acute Lymphoblastic Leukemiamedicine.drugMedical and Pediatric Oncology
researchProduct

Decayed, missing and filled teeth and dental anomalies in long term survived leukemic children: a prospective controlled study

2011

Objective: The aim of this prospective controlled study is the comparison between long-term children survived leukaemia and a control group in terms of the decayed, missing or filled permanent teeth (DMFT) and dental anomalies. Study design: Fifty-two long term children survived leukaemia, aged from 8 to 15 years (27 females, 25 males; mean age 11.5 years) were evaluated for the possible effects of the anti-leukaemic therapy on dental development and compared to a control group of 52 healthy children (27 females, 25 males, mean age 11 years). All long-term children who survived were at least 24 months in continuous complete remission. The study of the dental status with a routine oral exami…

MaleTime FactorsAdolescentDentistryOdontologíaOral hygienestomatognathic systemMicrodontiamedicineHumansProspective StudiesSurvivorsProspective cohort studyChildGeneral DentistryPermanent teethPaediatric patientsDental anomaliesbusiness.industryDMF IndexTooth Abnormalitiespediatric dentistry child leukemia leukemia survivorsMED/28 - MALATTIE ODONTOSTOMATOLOGICHEPrecursor Cell Lymphoblastic Leukemia-Lymphoma:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDental carestomatognathic diseasesLeukemia Myeloid AcuteOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryWho criteriaFemaleResearch-ArticleOdontostomatology for the Disabled or Special Patientsbusiness
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Population density and childhood leukaemia: results of the EUROCLUS study

1999

The EUROCLUS study assembled incidence data for 13,551 cases of childhood leukaemia (CL) diagnosed between 1980 and 1989 in 17 countries (or regions of countries). These were referenced by location at diagnosis to small census areas of which there were 25,723 in the study area. Population counts, surface area and, hence, population density were available for all these small areas. Previous analyses have shown limited extra-Poisson variation (EPV) of case counts within small areas; this is most pronounced in areas of intermediate population density (150-499 persons/km2). In this study, the data set was examined in more detail for evidence that variations in incidence and EPV of CL are associ…

Epstein-Barr Virus InfectionsCancer Researchmedicine.medical_specialtyPopulationBiologyRate ratioPopulation densitysymbols.namesakeEpidemiologymedicineHumansPoisson regressionChildeducationSmall-Area AnalysisPopulation Densityeducation.field_of_studyLeukemiaIncidenceIncidence (epidemiology)Precursor Cell Lymphoblastic Leukemia-LymphomaConfidence intervalEuropeOncologySmall-Area AnalysissymbolsDemography
researchProduct

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic proge…

2001

Stromal cell-derived factor-1alpha (SDF-1alpha) is a potent chemoattractant for hematopoietic progenitor cells (HPC), suggesting that it could play an important role during their migration within or to the bone marrow (BM). The integrin VLA-4 mediates HPC adhesion to BM stroma by interacting with CS-1/fibronectin and VCAM-1. It is required during hematopoiesis and homing of HPC to the BM. As HPC migration in response to SDF-1alpha might require dynamic regulation of integrin function, we investigated if SDF-1alpha could modulate VLA-4 function on BM CD34(hi) cells.CD34(hi) BM cells and hematopoietic cell lines were tested for the effect of SDF-1alpha on VLA-4-dependent adhesion to CS-1/fibr…

Cancer ResearchIntegrinsReceptors CXCR4Stromal cellIntegrinCD34Receptors Lymphocyte HomingVascular Cell Adhesion Molecule-1Bone Marrow CellsIntegrin alpha4beta1Hematopoietic Cell Growth FactorsCell LineColony-Forming Units Assaychemistry.chemical_compoundMiceLeukemia Megakaryoblastic AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaGeneticsCell AdhesionTumor Cells CulturedAnimalsHumansVCAM-1Cell adhesionMolecular BiologybiologyChemotaxisVLA-4Antibodies MonoclonalCell BiologyHematologyHematopoietic Stem CellsChemokine CXCL12Peptide FragmentsRecombinant ProteinsCell biologyFibronectinsFibronectinchemistryLiverbiology.proteinStromal CellsChemokines CXCHoming (hematopoietic)Signal TransductionExperimental hematology
researchProduct

Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therap…

2002

In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2). Fifty-five patients (41 male, 14 female) with a median age of 34 yea…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentHematopoietic growth factormedicine.medical_treatmentOpportunistic InfectionsNeutropeniaGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansProspective StudiesChemotherapyMitoxantroneHematologybusiness.industryCytarabineHematologyGeneral MedicineMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHematopoiesisSurgeryGranulocyte colony-stimulating factorLenograstimTreatment OutcomeFemalebusinessmedicine.drugAnnals of Hematology
researchProduct

Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.

2020

Rasburicase is a recombinant urate oxidase enzyme indicated for tumor lysis syndrome, a potential life-threatening oncologic emergency that occurs most commonly during initial chemotherapy for hematological malignancies. As a result of the defects in the physiological antioxidant pathway, erythrocytes of patients with glucose-6-phosphate dehydrogenase deficiency are not protected against the oxidizing stress exerted by hydrogen peroxide generated with the administration of rasburicase. The authors report a 14-year-old patient, diagnosed with T-cell acute lymphoblastic leukemia, who developed methemoglobinemia and hemolytic anemia with low oxygen saturation after starting steroids, hyperhydr…

Hemolytic anemiaMalemedicine.medical_specialtyAnemia HemolyticAdolescentUrate Oxidasemedicine.medical_treatmentMethemoglobinemiaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaGastroenterologyLow oxygen saturationhemic and lymphatic diseasesInternal medicinemedicineRasburicaseHumansChemotherapybusiness.industryHematologymedicine.diseaseHemolysisRecombinant ProteinsTumor lysis syndromeOncologySupportive psychotherapyPediatrics Perinatology and Child HealthbusinessMethemoglobinemiamedicine.drugJournal of pediatric hematology/oncology
researchProduct